1000368-95-5

Upstream product

• 608119-82-0 1-(4-(benzyloxy)-2-methylphenyl)ethanone 
• 1000369-06-1 (1S)-1,5-anhydro-2,3,4,6-tetra-O-benzyl-1-[2-(benzyloxy)-5-(4-bromobenzyl)-4-methylphenyl]-1-thio-D-glucitol 
• 1000369-08-3 2,3,4,6-tetra-O-benzyl-1-C-[2-(benzyloxy)-5-formyl-4-methylphenyl]-5-thio-D-glucopyranose 
• 898538-71-1 4-(benzyloxy)-5-bromo-2-methylbenzaldehyde 
• 1000369-07-2 2,3,4,6-tetra-O-benzyl-1-C-[2-(benzyloxy)-5-(1,3-dioxolan-2-yl)-4-methylphenyl]-5-thio-D-glucopyranose 
• 957773-99-8 2-(4-(benzyloxy)-5-bromo-2-methylphenyl)-1,3-dioxolane 
• 957774-01-5 4-benzyloxy-5-bromo-2-methylbenzoic acid 
• 875-59-2 4'-hydroxy-2'methylacetophenone 

Relevant academic research and scientific papers

Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes

The design and synthesis of a novel class of low-absorbable SGLT1 inhibitors are described. To achieve low absorption in the new series, we performed an optimization study based on a strategy to increase TPSA. Fortunately, the optimization of an aglycon m